It filed on time and stood behind its numbers. Of companies scoring zero, 4.0% were delisted, went bankrupt, restated or stopped filing within the following year.
Hover or tap a dot to see the filings behind that score.
Esperion Therapeutics, Inc. (the “Company”) has determined that it is unable to file, without unreasonable effort or expense, its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the “Form 10-Q”) with the Securities and Exchange Commission (the “SEC”) within the prescribed time period, as the Company has not yet completed its quarter-end financial close process for the quarter ended June 30, 2025. In connection with the preparation of its Form 10-Q, management identified certain errors in the earnings release for the quarter ended June 30, 2025, furnished with its Current Report on Form 8-K filed on August 5, 2025, and subsequently corrected such errors by furnishing an amended version of the earnings release with its Current Report on Form 8-K/A filed on August 11, 2025. The preliminary financial data in the amended earnings release is based on unaudited information and management estimates for the quarter ended June 30, 2025 as of the date of its issuance, and remains subject to completion of the Company’s financial closing procedures. As a result, the Company requires additional time to complete its financial closing procedures and finalize its condensed financial statements for inclusion in the Form 10-Q. The Company currently expects to file the Form 10-Q with the SEC as soon as practicable, and no later than the fifth calendar day following the prescribed due date, in accordance with Rule 12b-25. Forward-Looking Statements This Notification of Late Filing on Form 12b-25 contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements about the Company’s expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking
NT 10-Q, filed 2025-08-11 · accounts not ready
Esperion Therapeutics, Inc. (the “Company”) has determined that it is unable to file, without unreasonable effort or expense, its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the “Form 10-Q”) with the Securities and Exchange Commission (the “SEC”) within the prescribed time period, as the Company has not yet completed its quarter-end financial close process for the quarter ended June 30, 2025. In connection with the preparation of its Form 10-Q, management identified certain errors in the earnings release for the quarter ended June 30, 2025, furnished with its Current Report on Form 8-K filed on August 5, 2025, and subsequently corrected such errors by furnishing an amended version of the earnings release with its Current Report on Form 8-K/A filed on August 11, 2025. The preliminary financial data in the amended earnings release is based on unaudited information and management estimates for the quarter ended June 30, 2025 as of the date of its issuance, and remains subject to completion of the Company’s financial closing procedures. As a result, the Company requires additional time to complete its financial closing procedures and finalize its condensed financial statements for inclusion in the Form 10-Q. The Company currently expects to file the Form 10-Q with the SEC as soon as practicable, and no later than the fifth calendar day following the prescribed due date, in accordance with Rule 12b-25. Forward-Looking Statements This Notification of Late Filing on Form 12b-25 contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements about the Company’s expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking
reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.
Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.
See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.Every item above is a filing this company
made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not
investment advice